Novartis AG
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
(0.0% 1d) (-3.4% 1m) (-5.0% 1y) (0.0% 2d) (0.3% 3d) (-0.5% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap: $ 202,721,866,107
http://www.novartis.com
Sec Filling | Patents | 103914 employees
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
add to watch list Paper trade email alert is off
Press-releases
Viral Vector and Plasmid DNA Technologies: A Global Market Perspective
Published: 2024-04-17 (Crawled : 10:00) - prnewswire.com
TMO | News | $541.52 -1.05% 0.61% 2.1M
|
Health Technology
|
| O: -0.26%
H: 0.03%
C: -1.55%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.87%
H: 0.16%
C: -0.59%
RGNX | $16.08 -5.58% -5.91% 560K
|
Health Technology
|
| O: -1.43%
H: 2.27%
C: -3.18%
global dna market
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Published: 2024-04-17 (Crawled : 06:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.87%
H: 0.16%
C: -0.59%
kesimpta sclerosis novartis show benefits
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
Published: 2024-04-16 (Crawled : 14:00) - prnewswire.com
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: -1.24%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
PHG | $19.98 -0.84% 0.0% 500K
|
Health Technology
|
| O: -1.21%
H: 0.0%
C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -1.19%
H: 0.52%
C: -0.17%
VRNA | $16.1 -1.83% -1.86% 490K
|
Health Technology
|
| O: 1.65%
H: 2.43%
C: 0.87%
reach treatment research market
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -1.94%
H: 0.43%
C: -0.34%
OCUL | News | $5.86 -22.69% -29.35% 6.1M
|
Health Technology
|
| O: -1.03%
H: 3.66%
C: 1.7%
ocular key leaders
Biologic Therapeutics Market size is set to grow by USD 286.12 billion from 2023-2027, Introduction of biosimilars boost the market, Technavio
Published: 2024-04-15 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.75%
H: 0.85%
C: 0.85%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 2.1%
H: 0.0%
C: -2.52%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -1.19%
H: 0.52%
C: -0.17%
BAX | $39.65 0.33% 0.0% 2.3M
|
Health Technology
|
| O: -0.1%
H: 0.13%
C: -1.08%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.32%
H: 0.96%
C: 0.22%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -2.13%
H: 0.0%
C: 0.0%
BMRN S | $90.08 -0.43% -0.43% 940K
|
Health Technology
|
| O: -0.72%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.64%
H: 0.45%
C: -0.04%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
set therapeutics market
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Published: 2024-04-15 (Crawled : 18:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
fabhalta nephropathy for novartis show
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.32%
H: 0.04%
C: -0.56%
ARVN | $34.3 2.54% 2.48% 800K
|
Health Technology
|
| O: 8.28%
H: 0.56%
C: -4.75%
arv-766 protac license cancer treatment global protein for commercialization agreement
Novartis tender offer for MorphoSys AG commences
Published: 2024-04-11 (Crawled : 09:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.32%
H: 0.48%
C: -0.17%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.32%
H: 0.04%
C: -0.56%
MOR | $18.02 -0.11% -0.11% 590K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: -0.39%
for novartis
Central Nervous System (CNS) Stimulant Drugs Market size is set to grow by USD 6.48 billion from 2023-2027, Rise in incidence of CNS disorders boost the market, Technavio
Published: 2024-04-10 (Crawled : 09:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.67%
H: 0.0%
C: 0.0%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -0.29%
H: 0.0%
C: -1.97%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.6%
H: 1.03%
C: 0.52%
TMO | News | $541.52 -1.05% 0.61% 2.1M
|
Health Technology
|
| O: -2.01%
H: 0.0%
C: 0.0%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -1.16%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
JAZZ | $109.3 2.05% 2.01% 560K
|
Health Technology
|
| O: -1.71%
H: 0.57%
C: 0.37%
disorders system set market
Eczema Therapeutics Market size is set to grow by USD 5.81 bn from 2024-2028,high prevalence of atopic dermatitis boost the market- Technavio
Published: 2024-04-08 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 2.24%
H: 0.0%
C: -0.8%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -3.43%
H: 6.21%
C: 6.21%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.25%
H: 1.1%
C: -0.17%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.05%
H: 0.43%
C: -0.27%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.08%
H: 0.04%
C: -0.35%
BHC | $8.6 -0.69% 0.0% 2.1M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -7.27%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.77%
H: 1.63%
C: 0.35%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.18%
H: 0.3%
C: 0.19%
eczema dermatitis set therapeutics market
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Last 48 Hours Insiders Buying
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
QCRH P 118 | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
VUZI P 7500 | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
RMCF | $3.61 2.27% 2.22% 18K
|
Consumer Non-Durables
|
20:10